According to the Zhitong Finance App, Maiwei Bio-B (02493.HK) announced its 2026 interim results, with revenue of about 312 million yuan, up 209.06% year on year; gross profit of about 236 million yuan, up 198.67% year on year; R&D costs about 431 million yuan, up about 10% year on year; parent company owners should account for losses of about 522 million yuan, a year-on-year decrease of 5.37%.

According to the Zhitong Finance App, Maiwei Bio-B (02493.HK) announced its 2026 interim results, with revenue of about 312 million yuan, up 209.06% year on year; gross profit of about 236 million yuan, up 198.67% year on year; R&D costs about 431 million yuan, up about 10% year on year; parent company owners should account for losses of about 522 million yuan, a year-on-year decrease of 5.37%.